Pregnancy and Neonatal Outcomes in XXXX Treated with Regular @entity2690 or Fast-Acting @entity2690 Analogues.

@entity1 @entity6677 @entity6 @entity2690 @entity4053 @entity1017 @entity8455
BACKGROUND/AIMS: Fast-acting @entity2690 analogues (FAIAs) are being used more frequently during pregnancy. Previous studies comparing regular @entity2690 (RI) and FAIA consist primarily of @entity1 enrolled with pre-existing @entity6 ; therefore, we compared pregnancy and neonatal outcomes in @entity1 with @entity6677 . METHODS: We retrospectively investigated 197 pregnant @entity1 with @entity6 ( @entity6 ) requiring @entity2690 treatment for glycemic control. Individuals were divided into 2 groups: RI (n = 55) and FAIA (aspart or lispro; n = 142). Pregnancy outcomes, including caesarean section rate, and neonatal outcomes, including @entity8455 and ponderal index, were compared between groups. RESULTS: There were no significant differences in maternal baseline characteristics (age, parity, body mass index and @entity1017 ) between groups or in haemoglobinA1c before delivery. The frequency of emergency caesarean section (caesarean section after trial of labor) was not significantly different between groups (RI 16.7%, FAIA 24.7%; p = 0.452). There were no differences in frequencies of @entity8455 (RI 3.4%, FAIA 6.5%; p = 0.518), ponderal index (RI 2.65    0.5, FAIA 2.71    0.5; p = 0.322), cranial-thoracic circumference ratio (RI 1.07    0.06, FAIA 1.07    0.06; p = 0.386) or @entity4053 (RI 5.1%, FAIA 5.8%; p = 1.000). CONCLUSION: Our data indicate that FAIA achieves similar pregnancy and neonatal outcomes in @entity6 compared with RI. Considering @entity1 convenience, FAIA may be better to use during pregnancy.
